Colon AiQ: An Innovative Non-Invasive Test for Early Detection of Colorectal Cancer

With the aim of enhancing prevention in colorectal cancer, IQ Genomix introduces the new Colon AiQ molecular test.

Based on innovative molecular biology methods, the test provides high accuracy in detecting precancerous lesions and early-stage cancer in asymptomatic patients, offering a safe and effective solution for those who postpone colonoscopy.

Accuracy and Reliability: The Colon AiQ test has high accuracy with an overall sensitivity of 86% and specificity of 92%, making it the most effective option after colonoscopy for detecting precancerous lesions such as polyps and adenomas as well as colorectal cancer.

Easy Process, Fast Results: The test simply requires a blood draw, without the need for preparation, and results are available within 12 business days.

Benefits for Health and Society: Early detection with the Colon AiQ test helps improve survival rates, particularly when cancer is detected in early stages, where survival rates are as high as 90%.

The Colon AiQ test has 2 possible results:
– Negative signal: A negative result is reassuring and means that the test should simply be repeated the following year and generally standard colorectal cancer screening should be followed.
– Positive signal: If the test shows a positive result, then there is a possibility that colon cancer has developed and should definitely be investigated further by a gastroenterologist.

The Colon AiQ test is expected to change the landscape of colorectal cancer prevention, offering significant benefits to both patients and the healthcare system.

Learn more about the test: https://iqgenomix.com/en/colonaiq/